Skye Bioscience finalizes up to $22 million equity line with Redmile affiliate
The agreement, tied to Skye's planned acquisition of Redx Pharma, sets purchase terms and a warrant exercisable into 2030.
SEC filing
Latest
2 stories
Monday, August 24
Friday, August 14
Skye Bioscience and Redx Pharma to merge, form Fibrx Therapeutics with $125M financing
The combined company will focus on Redx's fibrosis pipeline, led by RXC008 for fibrostenotic Crohn's disease, with Phase 2 data expected in H2 2028.
SEC filing